BiologIC’s biocomputer invention to be used by Oxford Biomedica to develop viral vectors for cancer therapies
A leading gene and cell therapy specialist is to adopt BiologIC Technologies’ extraordinary biocomputer system.
Oxford Biomedica will use the Cambridge biotech company’s invention to develop viral vectors used in personalised cancer therapies.
BiologIC says its biocomputer technology offers a fast, cost-effective, scalable alternative to traditional drug development and classical industrial-scale manufacturing.
Richard Vellacott, CEO of BiologIC, said: “We are inventors of the biocomputer. Our ambition is that the biocomputer will drive a revolution in biology to help humanity address global problems, such as the existential threat of diseases, in sustainable and accessible ways.
“Oxford Biomedica has an outstanding track record for technology innovation, and so we are particularly delighted to collaborate with this leading gene and cell therapy group to support the development of powerful new processes and data insights using the biocomputer platform.”
Under the companies’ development agreement, BiologIC will develop new applications on its biocomputer platform for Oxford Biomedica, designed to enhance the novel viral vector manufacturing processes
The biocomputer is a programmable system for producing biology and data on demand.
Proprietary technology and IP are used in the design, fabrication and application of novel bio processing units - or BPUs - that operate on the biocomputer platform.
These BPUs are inspired by the integrated circuit that drove the information processing revolution and BiologIC says they have the potential to increase the biological processing power available to application developers significantly.
At their heart is 3D fluidic circuitry, capable of performing functions you would associate with a biology lab. In fact, the invention has been described as a ‘lab-in-a-box’ - one that plugs into a universal instrument, like silicon chips on a motherboard.
Additive manufacturing and integrated inline sensing are part of the company’s “full stack Industry 4.0 biocomputer”, which BiologIC wants to deploy to drive “a revolution in biology to feed, fuel, heal, build and compute in a sustainable and accessible way”.
The early focus of the company is on working with leading biology and technology organisations looking to implement new applications using real time biology and data.
Oxford Biomedica hopes the biocomputer will enable new processes, integrate traditionally discrete workflows and produce valuable insights from real-time data.